AZD2014

DRUG18 trials

Sponsors

AstraZeneca, Queen Mary University of London, Cambridge University Hospitals NHS Foundation Trust, UNICANCER, Samsung Medical Center

Conditions

Advanced Gastric AdenocarcinomaAdvanced Metastatic Breast CancerAdvanced Solid MalignanciesAdvanced and Metastatic Breast CancerCancer of StomachCore: Relapsed or Refractory Diffuse Large B-Cell LymphomaEndometrial CarcinomaEstrogen Receptor Positive Breast Cancer

Phase 1

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

CompletedNCT01026402

AstraZenecaAdvanced Solid Malignancies

Start: 2009-12-31End: 2014-08-31Updated: 2016-02-11

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

CompletedNCT01597388

AstraZenecaAdvanced Metastatic Breast Cancer

Start: 2012-05-08End: 2026-01-13Updated: 2026-02-24

Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer

CompletedNCT02064608

Cambridge University Hospitals NHS Foundation TrustProstate Cancer

Start: 2014-10-31End: 2018-06-30Updated: 2019-07-17

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

CompletedNCT02398747

AstraZenecaAdvanced Solid Malignancies

Start: 2015-03-17End: 2024-04-12Updated: 2024-12-17

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

Queen Mary University of LondonNon-squamous Cell Lung Cancer With KRAS Mutations, Non-squamous Cell Lung Cancer With Wild-type KRAS, Squamous Cell Lung Cancer +1

Start: 2015-06-30End: 2020-03-31Target: 118Updated: 2020-02-25

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

CompletedNCT02599714

AstraZenecaAdvanced and Metastatic Breast Cancer

Start: 2015-12-07End: 2023-11-23Updated: 2024-06-06

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

CompletedNCT02619864

Canadian Cancer Trials GroupGlioblastoma Multiforme

Start: 2016-12-22End: 2020-02-25Updated: 2023-08-04

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)

Centre Leon BerardEndometrial Carcinoma, Hormone Receptor Positive Tumor, Metastatic Carcinoma

Start: 2016-04-30End: 2024-12-31Target: 72Updated: 2024-02-13

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

WithdrawnNCT02780830

AstraZenecaCore: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma

Start: 2016-06-30End: 2019-04-30Updated: 2016-09-15

Phase 2

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer

TerminatedNCT01793636

Queen Mary University of LondonMetastatic Clear Cell Renal Carcinoma

Start: 2013-02-28End: 2015-11-30Updated: 2014-06-24

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

CompletedNCT02117167

UNICANCERNon-small Cell Lung Cancer Metastatic

Start: 2014-04-23End: 2023-12-31Updated: 2024-01-10

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

CompletedNCT02216786

Queen Mary University of LondonEstrogen Receptor Positive Breast Cancer

Start: 2014-01-16End: 2021-12-31Updated: 2024-12-02

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruitingNCT02299999

UNICANCERMetastatic Breast Cancer

Start: 2014-04-07End: 2025-12-31Updated: 2025-01-15

Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

TerminatedNCT02449655

Samsung Medical CenterAdvanced Gastric Adenocarcinoma

Start: 2015-02-12End: 2018-07-16Updated: 2019-05-20

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

CompletedNCT02831257

Massachusetts General HospitalMeningioma, Neurofibromatosis 2

Start: 2016-08-31End: 2020-10-01Updated: 2022-06-13

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy

TerminatedNCT03061708

Samsung Medical CenterStomach Neoplasms

Start: 2017-02-01End: 2018-11-16Updated: 2019-05-20

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General HospitalMeningioma

Start: 2017-10-17End: 2024-07-25Updated: 2022-10-18

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

TerminatedNCT03082833

Samsung Medical CenterCancer of Stomach

Start: 2017-02-01End: 2018-11-16Updated: 2019-05-20

Related Papers

Mapping the rapid growth of multi-omics in tumor immunotherapy: Bibliometric evidence of technology convergence and paradigm shifts

Human Vaccines & Immunotherapeutics2025-04-243 citations

Genomic instability in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/ IFCT1301 trial.

Journal of Clinical Oncology2024-06-011 citations

251P Genomic alterations of breast cancer patients with leptomeningeal disease: A retrospective analysis

ESMO Open2024-05-011 citations

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.

Journal of Clinical Oncology2023-06-011 citations

Genomics to select treatment for patients with metastatic breast cancer.

2022-09-07119 citations

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

JAMA Oncology2022-05-1272 citations

CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION

Neuro-Oncology2021-11-02

Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.

Journal of Clinical Oncology2021-05-209 citations

Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer—A CLIPP program INCA in collaboration with GINECO group.

Journal of Clinical Oncology2021-05-207 citations

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Genome Medicine2021-05-1853 citations

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.

2020-01-24221 citations

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

JAMA Oncology2019-08-2990 citations

Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation

Cancer Research2019-07-012 citations

Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation

Clinical Research (Excluding Clinical Trials)2019-07-01

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.

Journal of Clinical Oncology2018-05-205 citations

A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).

Journal of Clinical Oncology2018-05-205 citations

Treatment for Metastatic HER2 Breast Cancer Patients With High Loss of Heterozygosity

Oncology Times2017-08-04

A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results.

Journal of Clinical Oncology2017-05-2018 citations

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.

2017-03-2327 citations

CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).

Journal of Clinical Oncology2017-02-201 citations

6 more papers not shown